Text S1: Predicted downstream effects of high-impact genes on individual signaling and metabolic pathways
We also determined how the expression states of the previously predicted high-impact genes of Fig. 4 of the main manuscript putatively influence the expression of specific signaling or metabolic pathways.
To realize this, we used the network propagation algorithm of regNet [1] to quantify putative inhibitory (negative) or activating (positive) impacts of each high-impact gene on individual signaling and metabolic pathways (regNet: relative impacts). In-depth details to the underlying computations are provided in the appendix of [1] . Since expression profiles of oligodendrogliomas were very similar, we computed these impacts for the median expression profile of all 1p/19q co-deleted tumors. The two following sections summarize the predicted regulatory impacts of high-impact genes on individual cancer-relevant signaling and metabolic pathways.
Prediction of downstream effects of high-impact genes on individual cancer signaling pathways
We used network propagation [1] to predict how the previously described high-impact genes (see Fig. 4a of main manuscript) putatively influence the expression of genes of individual cancer-relevant signaling pathways ( Fig. S6a) . Generally, we observed three groups of genes (i) ELTD1 and ZMYM1 that activate specific pathways, (ii) KLK6 and THAP3 that inhibit and activate different pathways, and (iii) CTPS, CAP1, ZBTB17, and PTAFR that inhibit specific pathways. Similar to reported oncogenic functions [2] [3] [4] , we predicted that overexpressed ELTD1 in oligodendrogliomas may positively regulate the expression of genes of several pathways (ECM-Receptor interaction, MAPK signaling, PI3K-Akt signaling, Adherens junction, Notch signaling, Focal adhesion). Further, genes of the PI3K-Akt signaling pathway were also predicted to be positively regulated by overexpressed ZMYM1 and underexpressed KLK6. We also predicted that overexpressed THAP3 may positively regulate the expression of cell cycle genes and negatively regulate the expression of DNA base excision repair genes. Underexpressed CTPS may negatively regulate the expression of cell cycle and homologous DNA repair genes. Further, underexpressed ZBTB17 may negatively regulate the expression of base excision repair, Notch signaling and Wnt signaling genes. Underexpressed CAP1 may negatively regulate the expression of adherens junction and VEGF signaling genes. Moreover, we predicted that underexpressed PTAFR may negatively regulate the expression of genes of several signaling pathways (PI3K-Akt signaling, Focal adhesion, Cytokine receptor signaling, TGF-Beta signaling, VEGF signaling, JAK-STAT signaling, ErbB signaling, Apoptosis, mTOR signaling). This is in good agreement with its annotated functions [5] , but the putative role of PTAFR in oligodendroglioma development is complex. Oncogenic functions of PTAFR activating PI3K-Akt signaling were reported for esophageal cancer [6] . Our predictions indicate that the negative regulation of PI3K-Akt signaling by PTAFR could partly counteract cellular process supporting tumor development, whereas the negative regulation of pathways such as apoptosis could support the development of oligodendrogliomas.
( Fig. S6b) . Interestingly, we found that the underexpression of six genes (ATP5F1, PARK7, EIF3K, SEPW1, SDHB, COX6B1) in oligodendrogliomas compared to normal brain tissue led to a downregulation of the expression of genes of the oxidative phosphorylation pathway, whereas only the underexpression of HBXIP was predicted to activate the expression of this pathway. The downregulation of the oxidative phosphorylation pathway has been reported for many human carcinomas [7] . In accordance with the Warburg effect [8] , this downregulation is known to lead to a switch from oxidative phosphorylation as main source of energy production to glycolysis to adapt to anaerobic conditions, to account for disturbance of mitochondrial energy production, and to enable rapid energy production for tumor growth [9] .
Further, underexpressed SDHB was predicted to activate the expression of genes of the citrate cycle, whereas ATP5F1 was predicted to inhibit the expression of this pathway. The disturbance of the citrate cycle by SDHB deficiency has been reported for pheochromocytoma and paraganglioma leading to increased cellular succinate levels [10] . Increased succinate levels can inhibit alpha-ketoglutaratedependent enzymes [11] , which may contribute to known epigenetic alterations observed for oligodendrogliomas due to the presence of an IDH-mutation [12, 13] . Underexpressed PTAFR was predicted to downregulate genes of the inositol phosphate metabolism. Underexpressed RPL22 was predicted to activate the purine metabolism and to downregulate the pentose phosphate pathway. Overexpressed DPH5 was predicted to activate the expression of the purine metabolism and the pentose phosphate pathway.
Text S2: Subgroups of oligodendrogliomas show additional gene copy number mutations
We used hierarchical clustering to group the gene copy number profiles of the 133 histologically classified oligodendrogliomas with 1p/19q co-deletion from TCGA. We observed several less frequently occurring recurrent deletions (4q, 9q, 13q, 15q, 18q) and duplications (7p, 7q, 11q) affecting chromosomal arms of subgroups of these tumors (Fig. S1 ). The majority of these additional copy number mutations was observed for oligodendrogliomas of WHO grade III, but also several WHO grade II tumors had additional copy number mutations besides the 1p/19q co-deletion (median number of additional gene copy number mutations: 113.5 for OD II vs. 247.5 for OD III, Wilcoxon rank sum test, P = 0.008).
We tested if oligodendroglioma patients of WHO grade II and III with additional chromosomal arm mutations differ in survival from oligodendroglioma patients of WHO grade II and III that only showed a 1p/19q co-deletion, but we did not find a significant survival difference between both patient groups (log-rank test: P = 0.37, 55 patients with additional chromosomal arm mutations vs. 78 patients with 1p/19q co-deletion only, Fig. S2 ). Nevertheless, it is still likely that potential driver genes are also located in some of these additionally mutated regions. Since these were rare events, the sample sizes are too small to evaluate each individual region separately.
We further compared the additionally mutated chromosomal arms to chromosomal mutations reported for oligodendrogliomas of WHO grade III from the POLA cohort [14] . Despite of differences in observed mutation frequencies, we found that all mutations of chromosomal arms that we revealed for oligodendrogliomas of the TCGA cohort have also been observed in the POLA cohort (see Tab. 1 in main manuscript). This indicates that these chromosomal mutations did not occur at random, but rather represent less frequent recurrent mutational patterns that may influence the development of some oligodendrogliomas. Further, several of these mutated chromosomal arms were also observed in copy number profiles of single oligodendroglioma cells (e.g. deletions of chromosome 4 and 13 and duplications of chromosome 7 and 11) [15] .
Text S3: Impact of rare gene copy number mutations on signaling pathways
In the main manuscript, we have analyzed all differentially expressed genes located within the region of the 1p/19q co-deletion to identify genes with strong impact on the expression of signaling and metabolic pathways. The 1p/19q co-deletion was present in each of the 133 analyzed oligodendrogliomas (Fig. S1 ). Our utilized network-based impact quantification strategy further enabled the identification of potential tumor gene candidates within chromosomal regions that were recurrently observed in smaller groups of oligodendrogliomas (see Tab. 1 of main manuscript; deletions: 4q, 9q, 13q, 15q, 18q; duplications: 7p, 7q, 11q). We first determined for each subset of oligodendrogliomas with a specific chromosomal arm mutation all differentially expressed genes in comparison to normal brain tissue (q-value ≤ 0.05, see main manuscript for general details to methods used for gene expression analysis). We next analyzed all differentially expressed genes of each mutated chromosomal arm with our network-based impact quantification strategy to identify differentially expressed genes within these regions that had a strong impact on the expression of cancer-relevant signaling pathway genes (Tab. S6, paired Wilcoxon rank sum tests, q-value ≤ 0.1, see main manuscript for general details to impact computations). We were able to identify putative high-impact tumor candidate genes on 4q, 9q, 7p, 7q, 11q, and 18q. We again performed in-depth literature searches and analyzed gene annotations to characterize potential cancer-relevant functions of these genes. In the following, we summarize our findings for individual high-impact candidate genes identified on the different chromosomal arms. Predicted high-impact genes located on chromosomal arms rarely mutated in some oligodendrogliomas (Tab. S6, q-value ≤ 0.1). Gene expression: average log 2 -ratio of tumor to normal. loss: deletion of chromosomal arm. gain: duplication of chromosomal arm.
Differentially expressed genes

Chromosome 4: q-arm deletion in 13 of 133 oligodendrogliomas
The loss of the q-arm of chromosome 4 did not lead to underexpression of EMCN. We found that EMCN was overexpressed in oligodendrogliomas with 4q deletion compared to normal brain tissue. EMCN encodes a specific glycoprotein that has been found to inhibit cell adhesion to the extracellular matrix [16] . Further, PPID was underexpressed in the oligodendrogliomas with 4q deletion. PPID encodes an isomerase that assists in protein folding.
Chromosome 9: q-arm deletion in 6 of 133 oligodendrogliomas
RFK was underexpressed in oligodendrogliomas with 9q deletion in comparison to normal brain tissue.
RFK encodes a riboflavin kinase that converts riboflavin (vitamin B2) into flavin mononucleotide and flavin adenine dinucleotide (FAD), which are essential cofactors of dehydrogenases, reductases, and oxidases. RFK overexpression has been reported to protect prostate cancer cells against oxidative stress and cisplatin [17] . NAA35 was weakly underexpressed in oligodendrogliomas with 9q deletion in comparison to normal brain tissue. NAA35 encodes an acetyltransferase. Functional annotations suggest that NAA35 is involved in the regulation of apoptosis and proliferation of smooth muscle cells, but a role in cancer has not been reported so far. AKNA was weakly underexpressed in oligodendrogliomas with 9q deletion in comparison to normal brain tissue. AKNA encodes an AT-hook transcription factor that is known to specifically activate the expression of the CD40 receptor and its ligand CD40L/CD154. AKNA has been suggested to play a role in inflammation and neoplastic transformations [18] . A polymorphism within the AKNA gene has been associated with an increased risk of cervical cancer [19] . FBXW2 was underexpressed in oligodendrogliomas with 9q deletion compared to normal brain tissue. FBXW2 encodes a F-box protein involved in ubiquitin-mediated degradation of proteins. FBXW2 has recently been reported as tumor suppressor in lung cancer [20] . EGFL7 was underexpressed in oligodendrogliomas with 9q deletion compared to normal brain tissue. EGFL7 encodes a secreted endothelial cell protein with two epidermal growth factor-like domains. EGFL7 expression has been found to be positively correlated with cell proliferation, aggressiveness, and angiogenesis in gliomas [21, 22] .
Chromosome 18: q-arm deletion in 20 of 133 oligodendrogliomas
CXXC1 was weakly underexpressed in oligodendrogliomas with 18q deletion compared to normal brain tissue. CXXC1 encodes a transcriptional activator that binds specifically to non-methylated CpG motifs through its CXXC domain. No direct role of CXXC1 in cancer has been reported so far.
Chromosome 7: p-arm duplication in 8 of 133 oligodendrogliomas
EIF3B was overexpressed in oligodendrogliomas with 7p duplication compared to normal brain tissue.
EIF3B encodes a subunit of the eukaryotic translation initiation factor. Overexpression of EIF3B has been associated with malignant transformation of cells [23] and shown to be required for growth of bladder cancer [24] . A knockdown of EIF3B in a glioblastoma cell line has been shown to inhibit cell proliferation and to increase apoptosis [25] .
Chromosome 7: q-arm duplication in 12 of 133 oligodendrogliomas
DMTF1 was overexpressed in oligodendrogliomas with 7q duplication in comparison to normal brain tissue. DMTF1 encodes a transcription factor with a cyclin D-binding domain. DMTF1 has been reported to act as tumor suppressor in bladder cancer inhibiting cell growth and cell cycle progression in dependency of miRNA-155 [26] . CALD1 was overexpressed in oligodendrogliomas with 7q duplication compared to normal brain tissue. CALD1 encodes a cytoskeleton-associated protein. Expression of different splice variants of CALD1 have been reported to be involved in glioma neovascularization [27] . Overexpression of CALD1 has been associated with lymph node metastasis and poor prognosis of squamous cell carcinoma patients [28] . CALD1 has been associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer [29] . DNAJB6 was overexpressed in oligodendrogliomas with 7q duplication in comparison to normal brain tissue. DNAJB6 encodes a chaperone involved in protein folding and protein complex assembly. Reduced expression levels of DNAJB6 have been found in aggressive breast cancer influencing tumor growth and metastasis [30] . DNAJB6 is involved in tumor progression and metastasis formation [31] . Overexpression of DNAJB6 has been reported to promote invasion of colorectal cancer [32] . Nuclear localization of DNAJB6 has been associated with longer survival and reduced cell proliferation in esophageal cancer [33] .
Chromosome 11: q-arm duplication in 6 of 133 oligodendrogliomas
FAU was overexpressed in oligodendrogliomas with 11q duplication compared to normal brain tissue. 
Text S4: Impact of rare gene copy number mutations on metabolic pathways
In analogy to the characterization of genes with strong impact on the expression of cancer-relevant signaling pathway genes (Text S3), we characterized potential tumor gene candidates within chromosomal regions that were recurrently observed in smaller groups of oligodendrogliomas (see Tab. 1 of main manuscript; deletions: 4q, 9q, 13q, 15q, 18q; duplications: 7p, 7q, 11q). We first determined for each subset of oligodendrogliomas with a specific chromosomal arm mutation all differentially expressed genes in comparison to normal brain tissue (q-value ≤ 0.05, see main manuscript for general details to gene expression analysis). We next analyzed all differentially expressed genes of each mutated chromosomal arm with our network-based impact quantification strategy to identify differentially expressed genes within these regions that had a strong impact on the expression of metabolic pathway genes (Tab. S7, paired Wilcoxon rank sum tests, q-value ≤ 0.1, see main manuscript for general details to impact quantification). We were able to identify putative high-impact tumor candidate genes on 7p, 11q, 15q, and 18q. We again performed in-depth literature searches and analyzed corresponding gene annotations to identify potential cancer-relevant functions of these genes. In the following, we summarize our findings for individual high-impact candidate genes identified on the different mutated chromosomal arms. Predicted high-impact genes located on chromosomal arms rarely mutated in some oligodendrogliomas (Tab. S7, q-value ≤ 0.1). Gene expression: average log 2 -ratio of tumor to normal. loss: deletion of chromosomal arm. gain: duplication of chromosomal arm.
Differentially expressed genes directly affected by rare chromosomal arm mutations with strong impact on metabolic pathways
Chromosome 15: q-arm deletion in 12 of 133 oligodendrogliomas
COX5A was underexpressed in oligodendrogliomas with 15q deletion compared to normal brain tissue.
COX5A encodes for the cytochrome C oxidase subunit 5A involved in the transfer of electrons from cytochrome c to molecular oxygen. A knockdown of COX5A has been reported to suppress migration and invasion of lung cancer cells and increased COX5A expression has been found to be associated with poor prognosis of lung adenocarcinomas [39] . PKM2 was underexpressed in oligodendrogliomas with 15q deletion compared to normal brain tissue. PKM2 encodes a pyruvate kinase that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate to ADP, generating ATP and pyruvate.
PKM2 is involved in glycolysis and has a general role in caspase-independent cell death of tumor cells. PKM2 has been found to control glioma cell death and differentiation [40] . PKM2 has been reported to promote glucose metabolism and cell growth of gliomas [41] . Known roles of PKM2 in cancer were reviewed in [42] .
Chromosome 18: q-arm deletion in 20 of 133 oligodendrogliomas
ATP5A1 was underexpressed in oligodendrogliomas with 18q deletion compared to normal brain tissue.
ATP5A1 encodes a subunit of the mitochondrial ATP synthase. ATP5A1 has been found to be highly expressed in glioblastoma cells and in endothelial cells of the microvasculature [43] . ATP5A1 has been reported to be downregulated in renal carcinoma [44] . MBP was strongly underexpressed in oligodendrogliomas with 18q deletion compared to normal brain tissue. MBP encodes a major constituent of the myelin sheath of oligodendrocytes and Schwann cells in the nervous system. MBP expression has been reported for oligodendrogliomas more than two decades ago [45] . Our finding indicate that the loss of MBP expression in a subset of oligodendrogliomas has downstream impacts on the expression of metabolic pathway genes.
Chromosome 7: p-arm duplication in 8 of 133 oligodendrogliomas
GARS was weakly underexpressed in oligodendrogliomas with 7p duplication compared to normal brain tissue. GARS encodes a glycyl-tRNA synthetase that charges tRNAs with their corresponding amino acids. A clear role of GARS in cancer is not known so far, but cancer-associated activities of aminoacyltRNA synthetases have been reported for glioblastomas including GARS [46] .
Chromosome 11: q-arm duplication in 6 of 133 oligodendrogliomas
PYGM was underexpressed in oligodendrogliomas with 11q duplication in comparison to normal brain tissue. PYGM encodes a phosphorylase involved in glycogenolysis. Mutations of PYGM have been reported for breast cancer and reduced expression was associated with poor relapse-free survival [47] .
UBXN1 was overexpressed in oligodendrogliomas with 11q duplication in comparison to normal brain tissue. UBXN1 encodes a ubiquitin-binding protein. UBXN1 has been found to be a negative regulator of NF-kB signaling [48] . UBXN1 has been found to inhibit the tumor suppressor BRAC1 [49] .
Tumor suppressor and oncogenic functions of UBXN1 have been reported [50] . FAU was overexpressed in oligodendrogliomas with 11q duplication compared to normal brain tissue. FAU encodes a fusion protein consisting of a ubiquitin-like protein and a ribosomal protein. FAU has been reported as tumor suppressor in breast cancer regulating apoptosis [34] . We previously also predicted FAU as high-impact gene that strongly influenced the expression of signaling pathways (Text S3). ACAT1 was overexpressed in oligodendrogliomas with 11q duplication compared to normal brain tissue. ACAT1 encodes a mitochondrially localized acetyl-CoA acetyltransferase. Inhibition of the enzymatic activity of ACAT1 by Avasimibe inhibited cell growth by inducing cell cycle arrest and apoptosis in glioblastoma cell lines [51, 52] . Inhibition of ACAT1 has recently been shown to suppress growth and metastasis of pancreatic cancer [53] . SDHD was overexpressed in oligodendrogliomas with 11q duplication compared to normal brain tissue. SDHD encodes the succinate dehydrogenase complex D, which is essential for the oxidation of succinate. Germline mutations of SDHD have been reported for head and neck paragangliomas [54] . Generally, the succinate dehydrogenase consists of four subunits (SDHA, SDHB, SDHC, SDHD), has a general role in cellular energy metabolism, and is known to act as tumor suppressor [11] . We already found the high-impact gene SDHB located on the p-arm of chromosome 1 to be underexpressed in oligodendrogliomas compared to normal brain (see Fig. 4b main manuscript).
Thus, it is likely that the succinate dehydrogenase does not function properly in oligodendrogliomas.
Succinate dehydrogenase deficiency induces pseudohypoxia and leads to the accumulation of succinate inhibiting alpha-ketoglutarate-dependent enzymes [11] . This may further support the epigenetic reprogramming triggered by the IDH-mutation present in each oligodendroglioma [12, 13] . A potential molecular function of overexpressed SDHD in a subset of oligodendrogliomas is not known so far. The overexpression of SDHD might represent a response of oligodendroglioma cells with 11q duplication to the underexpression of SDHB. Interestingly, activation of the expression of the tumor suppressor CDKN1A in response to the loss of SDHD expression has been reported [55] . Thus, overexpressed SDHD might counteract the expression of CDKN1A to support cell proliferation. TMEM25 was underexpressed in oligodendrogliomas with 11q duplication compared to normal brain tissue. TMEM25 encodes a trans-trans-membrane protein. Expression of TMEM25 has been found to be correlated with better prognosis of breast cancer patients [56] . Epigentic downregulation of TMEM25 has been reported for colorectal cancer [57] . NRGN was highly underexpressed in oligodendrogliomas with 11q duplication compared to normal brain tissue. NRGN encodes a postsynaptic protein kinase substrate that binds calmodulin in the absence of calcium. We previously predicted NRGN as high-impact gene that strongly influenced the expression of signaling pathways and discussed this gene in Text S3. Frequently observed links among the ten networks have darker dot colors than less frequently observed links.
Regulator and target genes are aligned in chromosomal order from 1 to X and corresponding chromosomal arms are displayed by alternating black and grey bars. The red band around the main diagonal represents local chromosomal activator links. There are more links between genes of the same chromosomal arm than between genes of different chromosomal arms (Fisher's exact test, P < 1 × 10 −100 ). A similar band has also previously been observed in genome-wide gene regulatory networks learned from human gene expression profiles [59] or learned from human cancer cell lines [60] . A specific characteristic of the networks is the enrichment of activator links between the chromosomal arms 1p and 19q (Fisher's exact test, P < 1 × 10 −50 ).
Figure S4: Genes with many outgoing links in learned networks

